In the last year alone there were over 900 externally-funded research studies ranging from observational to complex interventional studies across Greater Glasgow and Clyde.

These were led by approximately 500 clinicians and recruited over 9,000 patients, with many more patients attending for follow up visits.

A futuristic phone app which can help users and clinicians detect the onset of a psychotic episode, novel gene therapies, and new targets for cancer treatment and heart failure new drug trials are just some of the medical projects pioneered in Glasgow in the last year.

Professor Julie Brittenden works both as a vascular surgeon for NHS Greater Glasgow and Clyde (NHSGGC) and as a research professor for the University of Glasgow.

And as the health board’s Research and Development Director she also leads the team responsible for enabling and facilitating the growing clinical research and innovation programme.

Julie said: “Glasgow has a proud history of world-leading medical research and development from the ultrasound to the use of antiseptic in surgery and the first ultrasound images of unborn babies.

“In 2018-2019 NHSGGC has continued to expand its research portfolio and increased the opportunities for patients and clinicians to take part in high quality research including accessing state of the art therapeutics, devices and testing new models of service delivery.

“This research is underpinned by joint NHSGGC and University of Glasgow state of the art dedicated clinical research facilities including imaging and close working across NHS departments, industry and academia.

“Glasgow is now home to one of the most ambitious clinical trial and innovation programmes in Europe delivering huge benefits to thousands of patients every year and helping attract some of the brightest staff to our city’s hospitals and universities.

“There is a real dynamism here and I think the Queen Elizabeth University Hospital has been a catalyst for change.”